{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:28:34Z","timestamp":1793914114064,"version":"4.8.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["ITMS 2014+: 313011V344"],"award-info":[{"award-number":["ITMS 2014+: 313011V344"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["1\/0090\/20"],"award-info":[{"award-number":["1\/0090\/20"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56147-8","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:37:48Z","timestamp":1780537068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational study"],"prefix":"10.1038","volume":"16","author":[{"given":"Zuzana","family":"Miertov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Leck\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Focko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Bolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Jozef","family":"P\u00e9\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Jurica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Galajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1n","family":"Mok\u00e1\u0148","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Samo\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"56147_CR1","volume-title":"Obesity and overweight","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Obesity and overweight (World Health Organization, 2024)."},{"key":"56147_CR2","volume-title":"Indicator metadata Registry details: Obesity","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Indicator metadata Registry details: Obesity (World Health Organisation, 2024)."},{"key":"56147_CR3","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2741\/4758","volume":"24","author":"RT Atawia","year":"2019","unstructured":"Atawia, R. T., Bunch, K. L., Toque, H. A., Caldwell, R. B. & Caldwell, R. W. Mechanisms of obesity-induced metabolic and vascular dysfunctions. Front. Biosci. 24, 890\u2013934 (2019).","journal-title":"Front. Biosci."},{"issue":"24","key":"56147_CR4","doi-asserted-by":"publisher","first-page":"10449","DOI":"10.3390\/ijms241310449","volume":"2023","author":"MS Popoviciu","year":"2023","unstructured":"Popoviciu, M. S., P\u0103duraru, L., Yahya, G., Metwally, K. & Cavalu, S. Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials. Int. J. Mol. Sci. 2023 (24), 10449 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"40","key":"56147_CR5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ijo.2015.220","volume":"2016","author":"ME Lean","year":"2016","unstructured":"Lean, M. E. & Malkova, D. Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence?. Int. J. Obes. 2016 (40), 622\u2013632 (2016).","journal-title":"Int. J. Obes."},{"issue":"1","key":"56147_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck, M. A. & Meier, J. J. Incretin hormones: Their role in health and disease. Diabetes Obes. Metab 20 (1), 5\u201321 (2018).","journal-title":"Diabetes Obes. Metab"},{"key":"56147_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","volume":"33","author":"AM Chao","year":"2021","unstructured":"Chao, A. M., Tronieri, J. S., Amaro, A. & Wadden, T. A. Semaglutide for the treatment of obesity. Trends Cardiovasc. Med. 33, 159\u2013166 (2021).","journal-title":"Trends Cardiovasc. Med."},{"key":"56147_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk, V. et al. Obesity management task force of the European association for the study of obesity. European guidelines for obesity management in adults. Obes. Facts 8, 402\u2013424 (2015).","journal-title":"Obes. Facts"},{"issue":"384","key":"56147_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"2021","author":"J Wilding","year":"2021","unstructured":"Wilding, J. et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM 2021 (384), 989\u20131002 (2021).","journal-title":"NEJM"},{"key":"56147_CR10","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden, T. A. et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA 325, 1403\u20131413 (2021).","journal-title":"JAMA"},{"key":"56147_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey, W. T. et al. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nat. Med. 28, 2083\u20132091 (2022).","journal-title":"Nat. Med."},{"key":"56147_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino, D. M. et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 327, 138\u2013150 (2022).","journal-title":"JAMA"},{"key":"56147_CR13","doi-asserted-by":"publisher","first-page":"e2231982","DOI":"10.1001\/jamanetworkopen.2022.31982","volume":"5","author":"W Ghusn","year":"2022","unstructured":"Ghusn, W. et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw. Open 5, e2231982 (2022).","journal-title":"JAMA Netw. Open"},{"key":"56147_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O'Neil","year":"2018","unstructured":"O\u2019Neil, P. M. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392, 637\u2013649 (2018).","journal-title":"Lancet"},{"key":"56147_CR15","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell, J. et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes. Metab. 19, 1242\u20131251 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"56147_CR16","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.3390\/jcm13206121","volume":"13","author":"A Oral","year":"2024","unstructured":"Oral, A., K\u00fc\u00e7\u00fck, C. & K\u00f6se, M. Real-world clinical effectiveness of liraglutide for weight management in Turkiye: Insights from the LIRA-TR study. J. Clin. Med. 13, 6121 (2024).","journal-title":"J. Clin. Med."},{"issue":"3","key":"56147_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey, W. T. et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr. Pract. 22(3), 1\u2013203 (2016).","journal-title":"Endocr. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56147-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56147-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:35:54Z","timestamp":1786664154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56147-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56147"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56147-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was conducted according to ethical standards. The research protocol was formally approved by local Ethical Committee (Jessenius Facutly of Medicine in Martin, Comenius University in Bratislava, Approval Code EK 38\/2024, approval Date 4\n                      th\n                      June 2024). All the enrolled subjects agreed with study participation and signed a written informed consent for study participation.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25398"}}